Latest Breaking News On - Thrombotic events - Page 1 : comparemela.com

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio

Analysis from a 10-month post-launch evaluation of the REMS Program finds 2.8% incidence of LVEF .

Hong kongUnited statesSouth koreaUnited kingdomGreat britainBristol myers squibbRoland chenPfizer allianceResearch for special populationsExchange commissionHead of developmentEuropean unionYork heart associationPfizer alliance theAmerican college of cardiologyAmerican college

Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting

– Sixteen oral presentations, as well as a plenary session and poster presentations, highlight new advances across eight of the Company’s medicines – Plenary Scientific Session will feature.

United kingdomUnited statesSan diegoPonatinib iclusigPabloj cagnoniIncyte corporationMillennium pharmaceuticals incDevelopment incyteHead of researchExchange commissionHealth disparitiesEuropean unionTakeda pharmaceutical companyAmerican society of hematology annual meetingTakeda pharmaceuticals internationalOutcomes research

Bristol Myers Squibb: Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023

Bristol Myers Squibb: Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Narinder bhallaSteve deitelzweigBristol myers squibbExchange commissionOchsner health systemEuropean society of cardiologyPfizer alliance thePfizer incNon valvular atrial fibrillationBristol myers squibb pfizerEuropean societySystem chairmanHospital medicineOchsner healthSenior vice presidentWorldwide medical

Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023

Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Bristol myers squibbSteve deitelzweigNarinder bhallaEuropean society of cardiologyPfizer alliance thePfizer incExchange commissionOchsner health systemNon valvular atrial fibrillationBristol myers squibb pfizerEuropean societySystem chairmanHospital medicineOchsner healthGdata martSenior vice president

Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023

25.08.2023 - The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) – (Pfizer NYSE: PFE) Alliance today presented results from ATHENS, a retrospective real-world data study, at the European Society of Cardiology (ESC) Congress 2023 showing that switching from Eliquis .

Bristol myers squibbNarinder bhallaExchange commissionPfizer alliance thePfizer incClinformatics data martSenior vice presidentWorldwide medicalEstablished brandsBristol myersHazard ratioConfidence intervalNon valvular atrial fibrillationApproved indicationsThrombotic eventsPremature discontinuation